Targeting genetic changes in aggressive lymphoma for better treatment
Official title: Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma
Funded at University of Tx Md Anderson Can Ctr · NIH-10986115 · Data updated 2026-11-12
This study is looking at how certain changes in genes on chromosome 18 can make diffuse large B-cell lymphoma (DLBCL) more aggressive, and it aims to create personalized treatments using new medicines that target these genetic markers to help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | December 1, 2020 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $396,838 |
| NIH project number | 5R01CA240839-05 |
| Project ID | NIH-10986115 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma, particularly those with aggressive subtypes associated with genetic alterations on chromosome 18.
✕Less likely to help
Patients with other types of lymphoma or those whose DLBCL does not exhibit the specific genetic changes being targeted may not benefit from this research.
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, which is often treated with chemotherapy and the anti-CD20 antibody, Rituximab. The study aims to identify genetic alterations on chromosome 18 that are linked to more aggressive forms of DLBCL, particularly focusing on the TCF4 and BCL2 genes. By using innovative protein-degrader molecules and inhibitors, the researchers hope to develop a precision medicine approach that tailors treatment based on these genetic markers, potentially improving outcomes for patients with this challenging disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with aggressive forms of DLBCL.
How similar studies have gone: Previous research has shown promise in targeting genetic alterations in various cancers, suggesting that this approach could be effective, although the specific targeting of 18q alterations in DLBCL is relatively novel.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Green, Michael Richard — University of Tx Md Anderson Can Ctr
- Study coordinator: Green, Michael Richard
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.